PPHM


Company Update (NASDAQ:PPHM): Peregrine Provides Strategic Update

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced that it intends to increase the size of its Board of Directors from four to up to seven …

Peregrine Pharmaceuticals (PPHM) Announces Fiscal Fourth Quarter Results; Shares Fall 15%

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced financial results for the fourth quarter and fiscal year (FY) ended April 30, 2017, and provided an update on its …

Peregrine Pharmaceuticals (PPHM) Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of promising new data from its Phase III SUNRISE trial of bavituximab in patients with previously treated …

Company Update (NASDAQ:PPHM): Peregrine Pharmaceuticals Announces Financial Results for the Third Quarter of Fiscal Year 2017

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced financial results for the third quarter of fiscal year (FY) 2017 ended January 31, 2017, and provided an update …

Peregrine Pharmaceuticals (PPHM) Announces Publication of Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the publication of positive proof-of-concept data for a novel exosome-based cancer detection platform.  Results of the study, conducted at University …

Company Update (NASDAQ:PPHM): Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced financial results for the second quarter of fiscal year (FY) 2017 ended October 31, 2016, and provided an update …

Company Update (NASDAQ:PPHM): Peregrine Pharmaceuticals Presents Data from Multiple New Preclinical Studies of Phosphatidylserine (PS)-Targeting Antibodies

Peregrine Pharmaceuticals (NASDAQ:PPHM) announced the presentation of positive data from multiple new preclinical studies of the company’s phosphatidylserine (PS)-targeting antibodies. Study results highlight …

Company Update (NASDAQ:PPHM): Peregrine Pharmaceuticals, Inc. Announces Presentation of Preclinical Data in Triple Negative Breast Cancer

Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) announced the presentation of preclinical study data demonstrating that phosphatidylserine (PS)-targeting antibodies similar to bavituximab are able to enhance …

Biotech Stocks: Fad or Trend?

By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …

Company Update (NASDAQ:PPHM): Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at ESMO 2016 Congress

Peregrine Pharmaceuticals (NASDAQ:PPHM) reported that top-line data from the Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts